C1 Inhibitor Deficiency (Type II)

Comprehensive Clinical Guide: C1 Inhibitor Deficiency (Type II)

1. Introduction and Clinical Overview

C1 Inhibitor Deficiency, specifically Type II Hereditary Angioedema (HAE-nC1-INH), is a rare, autosomal dominant genetic disorder characterized by a qualitative dysfunction of the C1 esterase inhibitor protein. Unlike Type I HAE, where the protein levels are low, Type II HAE involves the production of normal or elevated levels of a dysfunctional C1-INH protein.

This deficiency leads to the uncontrolled activation of the complement system, the contact-kinin system, and the intrinsic coagulation pathway. Clinically, this manifests as recurrent, unpredictable, and potentially life-threatening episodes of non-pruritic, non-pitting subcutaneous and submucosal edema. Because the condition is systemic and affects the permeability of the microvasculature, it poses significant diagnostic and management challenges for clinicians across immunology, emergency medicine, and internal medicine.

2. Etiology and Pathophysiology

The Molecular Mechanism

The C1-esterase inhibitor (C1-INH) is a serine protease inhibitor (serpin) that functions as the primary regulator of several plasma protease systems. In Type II HAE, mutations—typically located in the SERPING1 gene—result in the synthesis of a protein that is immunologically detectable but functionally inert.

The Contact-Kinin Cascade

The primary driver of edema in Type II HAE is the overproduction of Bradykinin. Under normal physiological conditions, C1-INH inhibits factor XIIa and kallikrein. When C1-INH is dysfunctional:
1. Factor XIIa is left unchecked, leading to massive conversion of prekallikrein to kallikrein.
2. Kallikrein cleaves high-molecular-weight kininogen (HMWK) to release bradykinin.
3. Bradykinin binds to B2 receptors on endothelial cells, causing profound vasodilation and increased vascular permeability.

3. Clinical Presentation and Staging

The clinical presentation of Type II HAE is heterogeneous. Symptoms typically begin in childhood or adolescence and worsen during puberty.

Common Clinical Features

• Cutaneous Edema: Non-pitting, non-pruritic swelling, most commonly affecting the face, extremities, and genitalia.
• Abdominal Attacks: Intense, colicky abdominal pain caused by edema of the intestinal wall, often mimicking surgical emergencies.
• Laryngeal Edema: The most dangerous manifestation, which can lead to rapid airway obstruction and asphyxiation if left untreated.

Clinical Staging/Grading (Severity Index)

While there is no universally standardized "staging" system like cancer, clinicians utilize a severity score based on attack frequency and anatomical location.

• Grade 1 (Mild): Infrequent cutaneous swelling; no airway involvement; manageable with on-demand therapy.
• Grade 2 (Moderate): Recurring attacks (monthly); abdominal involvement requiring ER visits; significant impact on Quality of Life (QoL).
• Grade 3 (Severe): Frequent attacks, history of laryngeal edema, or requirement for long-term prophylactic therapy.

4. Differential Diagnosis

Distinguishing Type II HAE from other forms of angioedema is critical because the treatment modalities are vastly different.

• Key Differentiator: In Type II HAE, the C1-INH antigen level is normal, but the functional activity is markedly low. This is the "Gold Standard" for identification.

5. Diagnostic Testing Protocols

A definitive diagnosis requires a combination of clinical history and laboratory evaluation.

1. C4 Levels: During an attack, C4 levels are almost universally low. Normal C4 levels between attacks do not rule out HAE, but low levels are highly suggestive.
2. C1-INH Functional Assay: This is the diagnostic cornerstone. A chromogenic assay is used to measure the ability of C1-INH to inhibit C1s or kallikrein.
3. C1-INH Antigen (Protein) Level: Measured via radial immunodiffusion or nephelometry. In Type II, this will be within normal range or elevated.
4. Genetic Testing: Sequencing of the SERPING1 gene can confirm the mutation, though it is not always necessary if functional tests are conclusive.

6. Management and Therapeutic Indications

Therapy is divided into three distinct pillars:

A. Acute Attack Treatment

The goal is to restore C1-INH levels or block the effects of bradykinin immediately.
* C1-INH Concentrate (Plasma-derived or Recombinant): Replaces the deficient/dysfunctional protein.
* Icatibant: A selective bradykinin B2 receptor antagonist.
* Ecallantide: A potent kallikrein inhibitor.

B. Short-term Prophylaxis

Indicated prior to high-risk procedures (e.g., dental work, intubation, surgery).
* Standard protocol involves C1-INH concentrate administered 1–6 hours before the procedure.

C. Long-term Prophylaxis

Indicated for patients with frequent, debilitating, or life-threatening attacks.
* Plasma-derived C1-INH (IV or Subcutaneous): Regular infusions.
* Lanadelumab: A monoclonal antibody that inhibits plasma kallikrein.
* Berotralstat: An oral, once-daily plasma kallikrein inhibitor.
* Androgens (Danazol): Rarely used now due to side effects, but historically effective in increasing liver production of C1-INH.

7. Risks, Side Effects, and Contraindications

• Androgens: Associated with hepatotoxicity, virilization, weight gain, and lipid profile alterations. Contraindicated in pregnancy.
• C1-INH Concentrates: Potential (though rare) risk of thromboembolic events or hypersensitivity reactions.
• Icatibant: Common injection site reactions (burning, erythema, swelling).
• General Risk: Misdiagnosis as allergic angioedema leads to the inappropriate use of antihistamines and corticosteroids, which are ineffective in HAE.

8. Prognosis and Long-term Outlook

The prognosis for patients with Type II HAE has improved dramatically over the last decade. With the advent of targeted therapies (kallikrein inhibitors and monoclonal antibodies), patients can achieve near-total symptom control.

• Mortality: Historically, mortality rates for undiagnosed HAE were high due to laryngeal edema. Modern awareness and availability of self-administered acute therapies have significantly reduced this risk.
• Morbidity: Chronic abdominal pain and the psychological burden of unpredictable attacks remain the primary drivers of morbidity.
• Life Expectancy: With proper management and access to emergency medication, the life expectancy of a patient with Type II HAE is comparable to the general population.

9. Frequently Asked Questions (FAQ)

Q1: Is Type II HAE the same as an allergy?
No. Type II HAE is a genetic deficiency of a protein regulator, not an IgE-mediated allergic reaction. Antihistamines will not work.

Q2: Can I get Type II HAE later in life?
Type II is hereditary. However, Acquired Angioedema (AAE) can present later in life and mimics HAE, but it is usually associated with underlying lymphoproliferative disorders.

Q3: Is the swelling painful?
Cutaneous swelling is usually described as tight or tense rather than overtly painful, but abdominal attacks are extremely painful due to bowel wall edema.

Q4: How often should I have my C1-INH levels checked?
Once the diagnosis is confirmed, routine monitoring of C1-INH levels is not typically required unless there is a change in clinical severity or a need to re-evaluate prophylactic strategy.

Q5: Can I have a normal C4 level and still have HAE?
It is rare, but possible. C4 levels are most reliable when measured during an active attack.

Q6: What is the risk to my children?
As an autosomal dominant condition, there is a 50% chance of passing the genetic mutation to each offspring.

Q7: Can stress trigger an attack?
Yes. Physical trauma, surgical stress, and emotional stress are well-documented triggers for HAE attacks.

Q8: Why are corticosteroids ineffective?
Because HAE is driven by the bradykinin pathway, not the inflammatory pathways commonly modulated by steroids.

Q9: Do I need to carry an EpiPen?
Patients with HAE should carry their specific rescue medication (Icatibant or C1-INH concentrate). An EpiPen is for anaphylaxis and is not indicated for HAE.

Q10: Can surgery be performed safely?
Yes, provided that short-term prophylactic treatment (C1-INH concentrate) is administered prior to the procedure to prevent stress-induced angioedema.

10. Conclusion

C1 Inhibitor Deficiency (Type II) remains a complex, high-stakes diagnosis that demands clinical vigilance. By focusing on the functional deficiency of the C1-INH protein and the subsequent bradykinin cascade, clinicians can differentiate this condition from more common allergic presentations. Modern therapeutic advancements have transformed the management landscape, shifting the focus from reactive emergency care to proactive, patient-centered, long-term disease control. Patients should be managed in close coordination with clinical immunology specialists to ensure that both acute and maintenance therapies are optimized for their specific phenotypic expression of the disorder.